Abstract:
T-lymphocytes are ideal targeting vehicles because (1) they are naturally equipped with trafficking capabilities, (2) they can undergo clonal expansion when they come in contact with antigen if given the appropriate mitogenic signals, (3) they release cytokines which recruit other inflammatoryhmmune cells, (4) they can initiate other arms of immunity at the tumor site and ( 5 ) they are capable of being engineered with powerful cytotoxins or enzymes. Both clonal expansion and recruitment of T-cells can greatly magnify targeted delivery, improving the therapeutic index of the intended diagnostic or treatment modality. Although lymphokine activated killer cells (LAK) and tumor infiltrating lymphocytes (TIL) have been tested in tumor targeting, the clonal frequency of tumorspecific lymphocytes is generally very low and <O.O 16% of administered lymphocytes arrive at the tumor sites, accounting for the limited efficacy and generalized toxicity of LAWTIL adoptive immunotherapy. Until the specific delivery of these cells is optimized, the potential of cell targeting cannot be explored. Quantitative analysis and trace-labeling of human lymphocytes for homing studies to human tumors in vivo have been limited by the unavailability of cell-labeling techniques and efficiency of gene transduction into T-cells. Issues unique to cellular targeting include homing properties of lymphocyte subpopulations (CD4+ vs CD8+ T-cells vs NK cells), clonal expansion of antigen-specific cells, and the cytotoxic potential of gene-modified T-cells.
T-lymphocytes die of apoptosis when their TCR is engaged, unless costimulatory molecules on their cell surface are activated. To enhance the survival and proliferation of T lymphocytes reacting against tumor cells that lack costimulatory molecules, we previously reported the successful transduction of G~2-specific-scFv-CD28 chimeric immune receptor (CIR) into primary human peripheral blood CD8+ T-cells, which became selectively expanded when cultured with cells expressing both the MHC class I and G D~. Thus, the transduced CIR carries out a functional costimulatory response that enhances their survival and selective expansion in the absence of natural costimulatory molecules. During the last funding period we have developed a novel affinity chromatography technique to rapidly clone efficient retroviral packaging cell lines. Using the pMSCVneo vector to carry the CIR and the packaging line GP+envAM 12, we can now transduce scFv-CD28-zeta-chain efficiently into primary human T-cells. The bulk culture achieves CIR monoclonality by 20 days of in vitro culture, achieving a 40-fold expansion in cell number within 2 months. The transduced T-cells kill tumors in vitro in an antigen specific manner and suppressed tumor growth when injected iv into SCID mice bearing human tumor xenografts. We have achieved CIR gene transduction in two separate antigen systems, one for GD2 (5F11 scFv) and one for the antigen p58 (8H9scFv). The novel antigen p58 was chosen because of its broad and usually homogeneous distribution in human solid tumors, and most importantly, their absence on cell membranes of normal human tissues. In separate experiments, we have shown that Tcells transduced with the herpes simplex viral thymidine kinase (HSV-tk) gene can be radiolabeled with '311-FIAU to a safe nuclear radiation dose. Using a dicistronic construct we are inserting chimeric immune receptor plus HSV-tk into T-cells to allow such their trafficking to be radioactively monitored. We plan to study the role of cytokines, chemoreceptors and CD4 helper T-cells in recruiting CD8+ transduced T-cells to the tumor site. These studies should provide us with an adoptive cell therapy approach to target cytotoxicity to human tumors, and a lymphocyte tracking tool to study delivery to the tumor sites, to determine if they proliferate locally andor recirculate. Such pharmacologic information is crucial for optimizing gene-modified T-cells in future clinical trials. 
Retroviral mediated gene transfer of chimeric immune receptor into primary human T-cells 3G6-scFv-CD28
A CIR consisting of 3G6-scFv and the signal transduction domain of CD2858 was constructed and high-titer producer cells were generated from the PG13 packaging cell line, with a titer of 7x1 O5 infectious particles per ml. PBMC were activated with phytohemagglutinin A and exposed to virus for 18 hours in the presence of polybrene (4 ug/ml). Three days after infection 28% to 40% of the CD3+ PBMC cells stained positively for the vector-encoded receptor in both CD4+ and CD8+ subsets. By FACS the transduced cells reacted with all 5 of 5 anti-idiotypic antibodies (i.e. Idio-2, C2H7, A2A6, C4E4, A1G4).8' By western blots, the scFv-CD28 chimeric protein (36 kDa in NIH 3T3 fibroblasts and -40 kDa in Jurkat cells) was expressed as a dimer. The engagement of the 3G6-CD28 on Jurkat cells by the anti-idiotypic antibody A 1 G4 triggered the association 85 kDa regulatory subunit of PI3-kinase with the phosphorylated CD28. IL-2 secretion by transfectants stimulated with immobilized anti-CD3 MoAb required costimulation by either anti-CD28 MoAb 9.3, or AlG4, or short term culture with tumor cells expressing GD2. In contrast, in transfectants with the truncated 3G6-CD28 where CD28 signaling is disabled, or irrelevant transgene such as NTP (NGFR'", low affinity nerve growth factor receptor) AlG4 had no effect. The costimulatory effect of GD2-positive EL4 was completely abolished by the addition of GD2-specific F(ab')2. Thus, 3G6-CD28 specifically recognizes cell-surface GD2, leading to CD28-dependent signaling, including IL-2 secretion. 3G6-CD28-transduced T lymphocytes selectively survived CD3-dependent cell death in the presence of anti-idiotype A1 G4. In addition, A 1 G4 MoAb induced preferential expansion of 3G6-CD28-transduced primary T lymphocytes. Corecognition of MHC-peptide complexes and GD2 selectively activated PBMC expressing 3G6-CD28. CD8+ T cells transduced with 3G6-CD28 remained a constant fraction of all T cells (10*2%) when cocultured either with 3T3 cells alone, 3T3-A2.1, 3T3-A2.1/B7, or 3T3-GD2, but steadily increased to 32&4% by day 12 if exposed to 3T3-A2.1/GD2. In control cultures, cells expressing 3G6-CD28TR or NTP remained unchanged. Thus, the increase in the fraction of 3G6-CD28-positive CD8+ T cells required both HLA A2.1 and GD2, which, on the other hand, had no effect on the transduced CD4+ subset. The same result was achieved in cultures of transduced CD8+ T cells in the absence of CD4+ cells. These data established that the engagement of 3G6CD28 with cell-surface GD2 antigen provides a powerful costimulatory signal to T cells specific for GD2-positive target cells.
sc8H9-CD28-hTCR-C and scSFll-CD28-hTCR-C, The hCD8a leader-scFv-CD28 were ligated
to hTCR-cchain to produce the gene hCD8-leader-8H9scFv-hCD28~~-hCD28,,~,-TCR< and hCD8-leader-5F 1 1 S C F V -~C D~~T M -~C D~~, ,~, -T C R < .
These sequences were verified and ligated into the pMSCVneo vector, and used to transfect the packaging line GP+envAM 12 bearing an amphotropic envelope and selected in G4 18.
3. Use of anti-idiotype technology for rapid enrichment and cloning of producer lines by affinity column or cell sorting Anti-linker antibody may be useful in monitoring scFv gene expression. However, its efficiency depends on the accessibility of the scFv-linker portion. Although purified antigens can also be used to monitor scFv expression, certain classes (complex carbohydrates or unstable antigens) can be difficult to prepare and their chemistry highly variable. Without a standardized reagent for affinity purification or enrichment of virus producer cells, as well as monitoring and sorting of transduced lymphocytes, CIR technology remains inefficient. A dicistronic construct consisting of scFv-CD28-y and green fluorescent protein (GFP) exploited the latter to monitor gene transduction and to enrich producer lines.47 Although GFP can validate the gene transfer process, its added immunogenicity and its safety in clinical applications remain uncertain. Anti-idiotypic antibodies Number of days in culture are frequently used as antigen-mimics for infectious diseases and Internal image rat anti-idiotypic antibodies can be conveniently produced against mouse MoAb. Since large scale production of clinical grade MoAb is now routine, anti-idiotypic antibodies may be ideal surrogates especially if the antigen is not readily available.
In addition, the biochemistry of immunoglobulins in positive selection (panning, affinity chromatography, sorting) and binding assays is wellknown and is easy to standardize. Here we demonstrate that an anti-idiotypic MoAb against 8H9 can be used as a surrogate antigen for cloning CIR into primary human lymphocytes, i.e. a CIR of 8H9scFv, human CD28 and human TCR-I; chain. While previous studies showed that anti-idiotypic antibody can enhance cytotoxicity of scFvyR-gene modified murine cytotoxic T-cell line,84 we now demonstrate that anti-idiotypic MoAb, besides allowing rapid affinity enrichment of producer cell line and monitoring of surface scFv expression, induces clonal expansion of CIR-modified primary human lymphocytes. Highly cytotoxic lymphocytes can be propagated in vitro undergoing lo6 fold expansion over a period of 6 months.
The retroviral producer lines were affinityenriched using MACS goat anti-rat IgG MicroBeads on the MiniMACS system (Miltenyi Biotec, Auburn, CA). Following each enrichment, viral supernatant from the producer line was used to infect the indicator cell line K562. Surface 8H9scFv expression on both the producer lines and the transfected K562 (4 days after infection) were measured by immunofluorescence using anti-idiotypic antibody 2E9. With each successive affinity enrichment ( Figure 1A and IC) of producer line and subsequent successive subcloning (Figure 1B and lD) , the surface expression (mean fluorescence) of 8H9-scFv increased and became more homogeneous for the producer clones ( Figure 1A In the presence of 100 U/ml of IL2 and solidphase anti-idiotypic antibodies, PBMC from 4 patients with stage 4 neuroblastoma off chemotherapy ( Figure  3B ), two CTL sampless5 ( Figure 3A ) and 4 fresh blood specimens from two normal volunteers ( Figure 3C ), were expanded in vitro following CIR-gene transduction. Continual expansion (lo3 to lo8 fold) was achieved after 150-200 days of culture, with a doubling time ranging from 5 to 10 days. 8H9scFv average gene copy number, transcript level, and surface expression were studied in these samples (Figure 4) . The scFv-positive population enriched quickly during the first 20 days of culture in the absence of 2E9 ( Figure 4A ). As expected, the gene copy number and transcript level also plateaued with similar kinetics (Figure 4B ). When the scFv-positive population became >95%, an average of 4.5 gene copies per cell (range 2-9) was detected, which remained relatively stable throughout the extensive length of in vitro culture. ScFv expression was typically >95% throughout 6 months of culture ( Figure 4A ). The proportion of CD8+ cells versus CD4+ cells increased steadily to >50% by day 40 of culture, and decreased slowly over 3-4 months. At concentrations of IL-2 <50 U/mL, CD4+ cells outgrew the CD8+ population even faster (data not shown).
4
Transduced lymphocytes mediated non MHC-restricted antigen-specific cyto-toxicity in vitro against neuroblastoma and rhabdomyosarcoma cell lines In vitro cytotoxicity against NMB-7 ( Figure 5A ) and LAN-1 ( Figure 5B ) neuro-blastoma, or rhabdomyosarcoma HTB-82 ( Figure 5C ) were efficient. Antigen-dependence was demonstrated by the inhibition of cytotoxicities by MoAb 8H9. Daudi cell line ( Figure 5D ) was not killed because it was antigen-negative. This cytotoxicity was independent of target HLA expression or HLA types (data not shown). Unmodified lymphocytes from the same donor, cultured under the same conditions (100 U/ml of IL2), did not show antigen-specific killing (Figures 5) . Control (5F 1 1 scFv) CIR modified lymphocytes also did not show antigen-specific killing of HTB82 (data not shown). In Elispot assays, IFN-)I secretion was detected when transduced lymphocytes were stimulated with antigen-positive tumors (NMB7 and HTB82) but not antigen-negative controls (Daudi, data not shown). Tumor cytotoxicity was demonstrated in CIR-gene modified Tlymphocytes whether they were derived from volunteers or from patients. This observation is important since T cells in patients and animals with growing tumors can have be defective in signal transduction.86 Whether these cells will consistently demonstrate antitumor effect in vivo, especially in the tumor environment, will require further studies.
5.
Targeting CIR-modified T cells to xenografts in SCID mice: developing an adoptive cell therapy model. 8H9scFv-CIR gene-modified lymphocytes suppressed HTB82 tumor growth, when mixed at 1:l ratio at the time of tumor implantation (data not shown). The in vivo anti-tumor effect of 8H9scFv-CIR gene-modified lymphocytes was then tested in an established tumor model. Human rhabdomyosarcoma was strongly reactive with 8H9, but not with 5F11 (anti-GDz) antibodies. 5FllscFv-CIR gene-modified and IL-2 cultured lymphocytes were used as controls cells in adoptive therapy. 5F 1 1 scFv-CIR contained the same CD28-TCRG construct used for 8H9scFv-CIR. Experiments were initiated when tumors grew to around 0.8 cm diameter. Control groups (Figure 6) were injected with either (1) no T cells but anti-idiotype 2E9 ip [A], (2) Day of treatment i
